INA Antibody

What is alpha-internexin (INA) and why is it significant in neuroscience research?

Alpha-internexin (INA) is a Class-IV neuronal intermediate filament protein with a molecular weight of approximately 55-66 kDa that is predominantly expressed in the central nervous system . It plays a crucial role in neuronal morphogenesis and can self-assemble to form an independent structural network or cooperate with other neurofilament proteins like NEFL to form filamentous backbones . INA is expressed abundantly during early neuronal development and is later downregulated in many neurons, though some mature neurons continue to express it as their only neurofilament subunit .

Its significance in research stems from its:

• Role as a neuronal marker specific to the CNS

• Involvement in neuronal development and regeneration

• Association with neurodegenerative disorders including neurofilament inclusion body disease (NFID)

• Identification as a target autoantigen in neuropsychiatric lupus

What are the most common applications for INA antibodies in neuroscience research?

INA antibodies are versatile tools for neuroscience research with multiple validated applications:

The epitope recognized by some INA antibodies (particularly clone 1D2) is in the C-terminal non-helical extension of the protein and is unusually resistant to aldehyde fixation, making these antibodies ideal for studies of paraffin-embedded formalin-fixed histological sections .

How can INA antibodies be used to distinguish different neuronal populations in experimental models?

INA antibodies serve as powerful tools for neuronal classification due to the differential expression patterns of alpha-internexin across neuronal populations:

• Developmental studies: Since INA is expressed early in neuronal development before other neurofilament proteins, anti-INA antibodies can identify developing neurons .

• Neuronal subtype mapping: Some mature neurons express only alpha-internexin as their neurofilament subunit, while others express it alongside the neurofilament triplet proteins (NF-L, NF-M, NF-H) .

• Neuronal regeneration: INA is markedly upregulated during neuronal regeneration, making INA antibodies valuable for studying neural repair processes .

Methodological approach:

• Use INA antibodies in combination with other neuronal markers (NeuN, MAP2) for comprehensive characterization

• Implement double or triple immunofluorescence labeling to visualize co-expression patterns

• Compare expression levels across developmental stages using quantitative Western blotting

• Correlate INA expression with functional neuronal properties using electrophysiological recordings

What is the relationship between INA and autoimmune disorders, and how can INA antibodies be used to study these conditions?

Alpha-internexin has been identified as a target autoantigen in neuropsychiatric lupus (NPSLE), making it relevant for autoimmune research . Studies have shown that:

• Anti-INA autoantibodies are present in approximately 50% of NPSLE sera

• More than 40% of NPSLE cerebrospinal fluid (CSF) samples show positivity for anti-INA antibodies

• The titer of anti-INA antibodies in both serum and CSF correlates with disease activity

Research methodologies:

• ELISA assays using purified recombinant INA (rINA) can detect anti-INA autoantibodies in patient samples

• Immunoblotting with rINA can be used to confirm specificity of autoantibodies

• Indirect immunofluorescence on rat cerebral, spinal cord, or cerebellar tissue can visualize binding patterns

• Pre-absorption experiments with rINA can confirm specificity of autoantibody binding

This approach offers insights into the pathogenesis of NPSLE and potential biomarkers for disease activity monitoring.

How should researchers validate the specificity of commercial INA antibodies for their particular experimental system?

Rigorous validation is essential for ensuring reliable results with INA antibodies. A comprehensive validation strategy includes:

• Multiple detection methods:

  • Western blotting should show a single band at ~55-66 kDa (species-dependent)

  • Immunostaining patterns should match known INA distribution in tissues

• Positive and negative controls:

  • Positive: Brain tissue (especially CNS samples)

  • Negative: Non-neuronal tissues (e.g., liver, kidney)

  • Knockout/knockdown controls where available

• Cross-reactivity assessment:

  • Test antibody on multiple species if cross-reactivity is claimed

  • Evaluate potential cross-reactivity with other intermediate filament proteins

• Blocking experiments:

  • Pre-incubate antibody with recombinant INA to demonstrate specific binding

• Epitope mapping:

  • Determine which region of INA the antibody recognizes (e.g., C-terminal non-helical extension for clone 1D2)

What are the optimal fixation and sample preparation protocols for INA immunohistochemistry in different tissue types?

The choice of fixation method significantly impacts INA antibody performance, with different approaches suited to various experimental needs:

Formalin fixation (FFPE tissue sections):

• Many INA antibodies (especially clone 1D2) perform exceptionally well on formalin-fixed paraffin-embedded tissues due to the unusual resistance of the C-terminal epitope to aldehyde fixation

• Protocol:

  • Fix tissues in 10% neutral buffered formalin for 24-48 hours

  • Process and embed in paraffin

  • Section at 4-6 μm thickness

  • Deparaffinize and rehydrate

  • Perform heat-induced epitope retrieval (HIER) with citrate buffer (pH 6.0)

  • Block endogenous peroxidase activity with 3% H₂O₂

  • Block non-specific binding with 5% normal serum

  • Incubate with primary INA antibody (1:1000-1:5000) overnight at 4°C

  • Detect using appropriate secondary antibody system

Fresh-frozen tissue preparation:

• Offers better epitope preservation for some applications

• Protocol:

  • Flash-freeze tissue in OCT compound using isopentane cooled with liquid nitrogen

  • Section at 10-15 μm thickness

  • Fix briefly (10-15 minutes) in cold acetone or 4% paraformaldehyde

  • Proceed with standard immunostaining protocol

Cell culture preparation:

• For ICC applications on cultured neurons

• Protocol:

  • Fix cells in 4% paraformaldehyde for 15 minutes at room temperature

  • Permeabilize with 0.1% Triton X-100 in PBS for 10 minutes

  • Block with 5% normal serum in PBS for 1 hour

  • Incubate with primary INA antibody (1:250-1:500) overnight at 4°C

  • Detect with fluorescently labeled secondary antibodies

What troubleshooting approaches are recommended for inconsistent INA antibody staining results?

When encountering issues with INA antibody staining, systematic troubleshooting can identify and resolve problems:

Advanced troubleshooting for Western blotting:

• If multiple bands appear, adjust extraction conditions to prevent protein degradation

• Include protease inhibitors in lysis buffer

• For brain samples, use region-specific analysis as INA expression varies across brain regions

How can researchers optimize INA antibody dilutions for maximum sensitivity and specificity across different applications?

Optimization of antibody dilutions is critical for balancing sensitivity and specificity in INA detection:

Antibody titration approach:

• Perform serial dilutions of the antibody (e.g., 1:100, 1:500, 1:1000, 1:5000, 1:10000)

• Test each dilution on identical samples

• Select the highest dilution that provides consistent specific signal with minimal background

Application-specific recommendations:

Quantitative optimization:

• Calculate signal-to-noise ratio for each dilution

• Plot signal intensity versus antibody concentration to identify the inflection point where additional antibody yields diminishing returns

How can INA antibodies be utilized to study neurodegenerative diseases and their mechanisms?

INA antibodies have significant applications in neurodegenerative disease research:

Neurofilament Inclusion Body Disease (NFID):

• INA antibodies (clone 1D2) have been used to demonstrate that alpha-internexin is an abundant component of the inclusions in NFID

• This finding has contributed to diagnostic criteria for this serious neurodegenerative disorder

Methodological approach for studying protein aggregation:

• Double-label immunofluorescence with INA antibodies and other markers of protein aggregation (TDP-43, tau, α-synuclein)

• Quantify co-localization coefficients

• Analyze spatial relationship between INA and other aggregated proteins

• Correlate pathological findings with clinical phenotypes

Neuronal injury models:

• Since INA is upregulated during neuronal regeneration , it can serve as a marker for monitoring neural repair

• Sequential sampling and INA antibody staining can track regeneration processes chronologically

Applications in biomarker development:

• Quantitative assessment of INA in cerebrospinal fluid as a potential biomarker for neuronal damage

• Methods include:

  • ELISA development using INA antibodies

  • Immunoprecipitation followed by Western blot for specific detection

  • Multiplex approaches combining INA with other neuronal markers

What are the experimental considerations when using INA antibodies to study autoimmune conditions affecting the nervous system?

When investigating autoimmune neurological conditions with INA antibodies, several factors require careful consideration:

Patient sample handling for autoantibody detection:

• Collect both serum and cerebrospinal fluid (CSF) when possible

• Process samples consistently (standard centrifugation protocols)

• Store aliquots at -80°C to preserve antibody reactivity

Methodological approaches for autoantibody detection:

• ELISA: Coat plates with purified recombinant INA (2 μg/ml) and test diluted patient samples (serum 1:100, CSF undiluted or 1:10)

• Immunoblotting: Transfer rINA to membranes and probe with patient samples at appropriate dilutions (serum 1:200-1:1000, CSF 1:10-1:20)

• Indirect immunofluorescence: Use neuronal substrates (rat brain sections) to visualize binding patterns of patient autoantibodies

Control selection criteria:

• Include both healthy controls and disease controls (non-autoimmune neurological conditions)

• Age and sex-matched controls are essential for accurate interpretation

• For neuropsychiatric lupus studies, include SLE patients without neuropsychiatric manifestations

Correlation with clinical parameters:

• Track antibody titers longitudinally in relation to disease activity

• Analyze relationship between anti-INA antibody levels and specific clinical manifestations

• Consider integrating with other autoantibody testing (ANA, anti-dsDNA) for comprehensive assessment

What are the latest developments in antibody engineering techniques being applied to INA antibodies for enhanced research applications?

Recent advances in antibody engineering are creating new opportunities for INA antibody applications:

Computational design approaches:

• Deep learning and multi-objective linear programming methods are being applied to antibody design

• These approaches can optimize antibody properties while maintaining diversity in libraries

• Applications include:

  • Enhancing binding affinity while preserving specificity

  • Improving stability under various experimental conditions

  • Reducing background binding in complex neural tissues

Binding loop optimization:

• Techniques like CDR (complementarity-determining region) design are improving antibody-antigen interactions

• Methods such as OptCDR can generate CDR backbone conformations predicted to interact favorably with specific epitopes

Fragment-based approaches:

• Single-chain variable fragments (scFvs) against INA offer advantages for certain applications:

  • Better tissue penetration in thick sections

  • Reduced background in immunostaining

  • Compatibility with fusion proteins for multimodal detection

Recombinant antibody production:

• Phage display selection can identify antibodies with custom specificity profiles

• These can be either cross-specific (detecting multiple related proteins) or highly specific (detecting only INA)

• Methodological considerations include:

  • Selection of appropriate display system

  • Design of screening strategy

  • Validation of binding characteristics

These advanced engineering approaches are expanding the toolkit available to researchers working with INA, enabling more precise and versatile experimental designs.

How should researchers interpret unexpected patterns of INA staining that differ from published literature?

When encountering unexpected INA staining patterns, researchers should consider several factors before concluding that their results contradict established findings:

Systematic validation approach:

• Verify antibody specificity using alternative detection methods

• Confirm results with a second INA antibody targeting a different epitope

• Check for potential cross-reactivity with other intermediate filament proteins

• Examine technical variables (fixation, tissue processing, antigen retrieval)

Biological explanations for discrepant patterns:

• Developmental stage differences (INA expression changes during development)

• Species-specific variations in expression pattern

• Region-specific expression within the CNS

• Pathological conditions altering expression or localization

• Post-translational modifications affecting epitope accessibility

Methodological considerations:

• Document all experimental conditions thoroughly

• Compare fixation methods with those in published literature

• Assess antibody lot-to-lot variation

• Consider the possibility of novel findings rather than technical issues

Resolution strategies:

• Perform RNA-level validation (in situ hybridization, RT-PCR)

• Use genetic approaches (knockdown/knockout controls)

• Collaborate with groups that published the original findings

What experimental design approaches are recommended when studying changes in INA expression across different neurological conditions?

Robust experimental design is crucial for meaningful comparisons of INA expression across conditions:

Sample considerations:

• Use statistically appropriate sample sizes (power calculations based on expected effect size)

• Include age and sex-matched controls

• Consider region-specific analysis within the CNS

• Standardize tissue collection and processing protocols

Quantification approaches:

• For immunohistochemistry:

  • Use unbiased stereological counting methods

  • Implement automated image analysis with consistent thresholding

  • Express results as cell density or percentage of positive cells

• For protein quantification:

  • Use quantitative Western blotting with appropriate loading controls

  • Consider ELISA for absolute quantification

  • Include standard curves with recombinant INA

Experimental design models:

• Cross-sectional studies: Compare INA expression across different disease states

• Longitudinal studies: Track changes in expression over disease progression

• Intervention studies: Examine effects of treatments on INA expression

Controls and validation:

• Include positive controls (tissues known to express INA)

• Use negative controls (non-neuronal tissues)

• Validate findings with multiple antibodies or orthogonal methods

How can researchers integrate INA antibody-based techniques with other methodologies for comprehensive characterization of neuronal populations?

A multimodal approach combining INA antibody techniques with complementary methods provides more comprehensive insights:

Integrated methodological workflows:

• Combined protein-RNA analysis:

  • Pair INA immunostaining with RNAscope in situ hybridization

  • Correlate protein expression with transcript levels

  • Method: Sequential or simultaneous protocol on the same tissue section

• Functional-structural correlation:

  • Combine INA immunostaining with electrophysiological recordings

  • Correlate INA expression with functional neuronal properties

  • Method: Patch-clamp recording followed by post-hoc immunostaining

• Multi-omics integration:

  • Correlate INA immunohistochemistry findings with:

    • Transcriptomics (RNA-seq of the same region)

    • Proteomics (mass spectrometry profiling)

    • Epigenomics (ChIP-seq for regulatory mechanisms)

  • Method: Parallel processing of adjacent tissue samples

• Advanced imaging combinations:

  • Super-resolution microscopy with INA antibodies

  • Expansion microscopy for enhanced spatial resolution

  • Method: Optimize protocols for compatibility with both techniques

Data integration strategies:

• Use computational approaches to integrate multimodal datasets

• Apply machine learning for pattern recognition across modalities

• Implement spatial statistics to correlate findings across techniques

This integrative approach provides a more complete understanding of INA's role in neuronal biology and pathological conditions than any single technique alone.